News coverage about Fate Therapeutics (NASDAQ:FATE) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Fate Therapeutics earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.0493575035156 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
Several equities research analysts recently weighed in on FATE shares. Zacks Investment Research raised Fate Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Friday, January 19th. ValuEngine raised Fate Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub cut Fate Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 2nd. HC Wainwright reaffirmed a “hold” rating and issued a $12.00 price target on shares of Fate Therapeutics in a research note on Tuesday, March 20th. Finally, UBS cut Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 6th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Fate Therapeutics has an average rating of “Buy” and an average target price of $15.00.
Fate Therapeutics opened at $9.31 on Friday, according to MarketBeat.com. Fate Therapeutics has a 12 month low of $2.52 and a 12 month high of $14.45. The firm has a market capitalization of $571.93 million, a PE ratio of -9.13 and a beta of 1.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 9.29 and a current ratio of 9.29.
Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). Fate Therapeutics had a negative return on equity of 71.00% and a negative net margin of 1,046.08%. The company had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $1.82 million. Fate Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts anticipate that Fate Therapeutics will post -0.94 earnings per share for the current year.
About Fate Therapeutics
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.